Jump to main content

Leading the way on rare and serious diseases

We are a global biotechnology leader focused on serving patients’ needs. Our scientists use the latest technologies to develop and deliver innovative therapies that are used to treat rare and serious diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency, as well as transplantation and critical care.

You Are Not Alone

Logan and his family walking their dogs

We are different because we develop our innovative products to meet the needs of people, not because of the size of a sales market. For example, one of our therapies is designed to treat a disease that affects only about 300 patients in the United States. If you are in that group of 300 people, finding a treatment for your disease may seem almost impossible. We are here to help. Your condition may be rare, but you are not alone.

We work with patient groups, plasma donors, researchers, physicians, nurses, pharmacists and home healthcare companies to promote quality care, improve patient access to care, expand educational outreach efforts, and affect public healthcare policy. We know and understand our patients better than just about anyone and are proud to offer the broadest range of quality products in the industry, but we never stop innovating. We continue to introduce new innovations that help people with urgent medical needs or enhance current treatments. We are first and foremost focused on fulfilling our patients’ needs.

Partnerships with patient organizations

CSL Behring collaborates with rare disease patient organizations at the international, regional, national and local levels to promote quality medical care and services and to improve and expand educational and outreach efforts. Through these partnerships, we strive to raise public awareness and to enhance appropriate public policies for rare diseases.

In Europe, CSL Behring partners with EURORDIS, the European Organization for Rare Diseases. EURORDIS is a patient-driven alliance of representatives from patient organizations and others activein the field of rare diseases. EURORDIS’ mission is to build a strong pan-European community of patient organizations and people living with rare diseases, to be their voice at the European level, and, directly or indirectly, to fight against the impact of rare diseases on their lives.

As a member of the EURORDIS Round Table of Companies (ERTC) at the Ruby level, CSL Behring gave EURORDIS an unrestricted grant to support its communications activities. In addition, CSL Behring also contributed in the context of the EURORDIS Black Pearl Awards, the EURORDIS Membership Meeting (EMM) and the EURORDIS International Initiatives. 

In the United States, CSL Behring partners with the National Organization for Rare Disorders (NORD), an umbrella organization of patient advocacy organizations dedicated to individuals with rare diseases. NORD, along with its more than 260 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. CSL Behring serves on the NORD Corporate Council, a group of innovative companies who have been developing therapies for the treatment of rare disorders, which helps to find commonality and discuss legislative activity to ensure the continued development of rare disease therapies. CSL Behring has provided NORD with unrestricted grants in support of their annual Rare Disease Summit and to bolster its government affairs capabilities.

CSL Behring has been recognized by NORD over the years for manufacturing cutting-edge therapies, winning its Industry Innovation Award on multiple occasions, most recently in 2017 for the licensure of IDELVION®, a long-lasting recombinant factor IX therapy for the treatment of hemophilia B.

Logo Förderverein Deutsche AtemwegsligaIn Germany, CSL Behring is a member of Deutsche Atemwegsliga. The aim of this nonprofit association is to combat respiratory diseases through a range of activities such as educating people about the importance, spread, causes and control options of these diseases. The association promotes prevention, early detection, diagnosis and therapy and supports patients and their relatives in aftercare and rehabilitation.

Rare Disease Day logo

More information about Rare Disease Day

Learn More